Passage Bio to Participate in Upcoming Investor Conferences
March 28 2022 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced that
management will participate in the following upcoming virtual
investor conferences:
Guggenheim 3rd Annual Genomic Medicines & Rare
Disease Day Format: Fireside ChatDate: Thursday, March 31,
2022Time: 9:00 a.m. ET
21st Annual Needham
Virtual Healthcare ConferenceFormat: PresentationDate:
Wednesday, April 13, 2022Time: 2:15 p.m. ET
Chardan Genetic Medicines and Cell Therapy Manufacturing
Summit Format: PresentationDate: Tuesday, April 26,
2022Time: 11:30 a.m. ET
A live webcast of these events will be available on the
Investors & Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentations will be
available for 30 days following the events.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide
life-transforming genetic medicines for patients with CNS diseases
that replace their suffering with boundless possibility, all while
building lasting relationships with the communities we serve. Based
in Philadelphia, PA, our company has established a strategic
collaboration and licensing agreement with the renowned University
of Pennsylvania’s Gene Therapy Program to conduct our discovery and
IND-enabling preclinical work. This provides our team with enhanced
access to a broad portfolio of gene therapy candidates and future
gene therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies into
clinical testing. As we work with speed and tenacity, we are always
mindful of patients who may be able to benefit from our therapies.
More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:Stuart HendersonPassage
Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc.
Healthcare Communications312-961-2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2023 to Sep 2024